论文部分内容阅读
目的观察和评估含莫西沙星的化疗方案在耐多药肺结核治疗中的疗效。方法将97例耐多药肺结核患者分为治疗组(n=48)和对照组(n=49)。对照组采用的化疗方案为阿米卡星、利福喷丁、对氨基水杨酸钠异烟肼、丙硫异烟胺、吡嗪酰胺;治疗组在此基础上加莫西沙星,疗程为21个月。结果共有93例患者完成化疗疗程,其中治疗组46例,对照组47例。疗程结束时痰菌阴转率治疗组为87%,对照组为59.6%,治疗组明显高于对照组(P<0.01)。结论含莫西沙星方案治疗耐多药肺结核有助于痰菌阴转和病变吸收好转,药物不良反应少。
Objective To observe and evaluate the efficacy of chemotherapy regimens containing moxifloxacin in the treatment of multidrug-resistant pulmonary tuberculosis. Methods 97 patients with MDR-TB were divided into treatment group (n = 48) and control group (n = 49). In the control group, the chemotherapy regimens were amikacin, rifapentine, sodium isosuccinate, isoniazid, prothionamide and pyrazinamide. The treatment group was given ganisoxacin on the basis of the course of treatment 21 months. Results A total of 93 patients completed chemotherapy, including 46 cases in the treatment group and 47 cases in the control group. At the end of treatment, sputum negative conversion rate was 87% in the treatment group and 59.6% in the control group, which was significantly higher in the treatment group than in the control group (P <0.01). Conclusion Treatment of multidrug-resistant pulmonary tuberculosis with moxifloxacin regimen is conducive to the improvement of sputum negative conversion and pathological changes, with less adverse drug reactions.